PRODUCT COMPRISING AT LEAST ONE CDC25 PHOSPHATASE INHIBITOR IN COMBINATION WITH AT LEAST ONE OTHER ANTI-CANCER AGENT

A SUBJECT OF THE INVENTION IS A PRODUCT COMPRISING AT LEAST ONE CDC25 PHOSPHATASE INHIBITOR IN COMBINATION WITH AT LEAST ONE OTHER ANTI-CANCER AGENT FOR A THERAPEUTIC USE WHICH IS SIMULTANEOUS, SEPARATE OR SPREAD OVER TIME IN THE TREATMENT OF CANCER.ACCORDING TO THE INVENTION, THE OTHER ANTI-CANCER AGENT IS PREFERABLY CHOSEN FROM:- ANALOGUES OF DNA BASES SUCH AS 5-FLUOROURACIL;- TYPE I AND/OR II TOPOISOMERASE INHIBITORS SUCH AS FOR EXAMPLE CAMPTOTHECIN AND ITS ANALOGUES, DOXORUBICIN OR AMSACRINE;- COMPOUNDS INTERACTING WITH THE CELL SPINDLE SUCH AS FOR EXAMPLE PACLITAXEL (TAXOL);- COMPOUNDS ACTING ON THE CYTOSKELETON SUCH AS VINBLASTINE;- INHIBITORS OF THE TRANSDUCTION OF THE SIGNAL PASSING THROUGH THE HETEROTRIMERIC G PROTEINS;- PRENYLTRANSFERASE INHIBITORS, AND IN PARTICULAR FARNESYLTRANSFERASE INHIBITORS;- CYCLIN-DEPENDENT KINASE (CDKS) INHIBITORS;- ALKYLATING AGENTS SUCH AS CISPLATIN;- ANTAGONISTS OF FOLIC ACID SUCH AS METHOTREXATE;AND- INHIBITORS OF THE SYNTHESIS OF DNA AND CELL DIVISION CELL SUCH AS MITOMYCIN C.A FURTHER SUBJECT OF THE INVENTION IS (1R)-1-[((2R)-2-AMINO-3-[ (8S)-8-(CYCLOHEXYLMETHYL)-2-PHENYL-5,6-DIHYDROIMIDAZOL[1,2-A]PYRAZIN-7(8H)-YL-2-OXOETHYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USEFUL AS AN ANTICANCER AGENT.